Enhabit (EHAB) Expected to Announce Earnings on Wednesday

Enhabit (NYSE:EHAB) will likely be announcing its earnings results after the market closes on Wednesday, March 5th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $259.11 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Enhabit Stock Performance

Shares of EHAB stock opened at $8.43 on Tuesday. The firm has a market capitalization of $423.89 million, a price-to-earnings ratio of -3.63 and a beta of 1.83. The stock has a fifty day moving average of $8.13 and a 200 day moving average of $7.90. Enhabit has a 52 week low of $6.85 and a 52 week high of $11.74. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85.

Insider Buying and Selling

In other news, Director Jeffrey Bolton bought 4,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $8.69 per share, with a total value of $34,760.00. Following the completion of the acquisition, the director now owns 98,144 shares of the company’s stock, valued at approximately $852,871.36. This represents a 4.25 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stuart M. Mcguigan bought 15,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was purchased at an average price of $8.81 per share, for a total transaction of $132,150.00. Following the purchase, the director now owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. This represents a 47.15 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on EHAB shares. Leerink Partners reaffirmed a “market perform” rating and issued a $8.00 target price (down from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. Jefferies Financial Group upgraded shares of Enhabit from a “hold” rating to a “buy” rating and raised their price objective for the stock from $8.25 to $9.50 in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Enhabit presently has an average rating of “Hold” and a consensus target price of $8.75.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.